NEW YORK, Dec. 07, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Apogee Enterprises, Inc. (NASDAQGS: APOG)
Class Period: June 28, 2018 to September 17, 2018
Lead Plaintiff Deadline: January 4, 2019

Throughout the class period, Apogee Enterprises, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Apogee lacked the required labor force in place to ramp-up its production; (ii) Apogee was unable to hire, train and retain new employees; (iii) Apogee’s productivity and margins would be negatively impacted; and (iv) as a result of the foregoing, Defendants’ statements about the Company’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Get additional information about the APOG lawsuit: http://www.kleinstocklaw.com/pslra-1/apogee-enterprises-inc-loss-submission-form?wire=3

Trevena, Inc. (NASDAQGS: TRVN)
Class Period: May 2, 2016 to October 9, 2018
Lead Plaintiff Deadline: December 10, 2018

The complaint alleges that during the class period Trevena, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) during its meetings with the FDA prior to the start of the Class Period, Trevena had been advised that the FDA did not agree with certain aspects of the design of the Phase III clinical trial of Olinvo, including the proposed dosing, the proposed primary endpoint and the proposed non-inferiority margin for comparing morphine to Olinvo; (b) unless Trevena demonstrated that Olinvo was at least equally effective to morphine in treating post-operative pain in the Phase III clinical trial, the FDA would be unwilling to consider any secondary benefits Olinvo might confer in terms of reduced opioid-related adverse effects ("ORAEs"); (c) the FDA disagreed with how the safety data was being compiled in the Phase II clinical trial; (d) because the FDA did not agree with major tenants of the design of the Phase III clinical trial, it was highly unlikely that the FDA would find the data obtained from that clinical trial sufficient to support Trevena’s NDA; (e) because the Phase III clinical trial data being derived would not likely be deemed sufficient to support the NDA for Olinvo, the Company would not be able to market Olinvo as soon as it was leading the market to expect, if ever; and (f) as a result of the foregoing, the Company was not on track to achieve the commercial sales revenues from Olinvo as soon as Defendants had led the market to expect during the Class Period, if ever.

Get additional information about the TRVN lawsuit: http://www.kleinstocklaw.com/pslra-1/trevena-inc-loss-submission-form?wire=3

Alphabet Inc. (NASDAQ: GOOG)
Class Period: April 24, 2018 to October 10, 2018
Lead Plaintiff Deadline: December 10, 2018

Alphabet Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Google exposed the private data of hundreds of thousands of Google+ social network users; (2) Google actively concealed this data breach for several months; (3) this conduct violated Google’s purported data privacy and security policies; (4) discovery of the foregoing conduct could foreseeably subject Alphabet to heightened regulatory scrutiny; and (5) as a result, Alphabet’s public statements were materially false and misleading at all relevant times.

Get additional information about the GOOG lawsuit: http://www.kleinstocklaw.com/pslra-1/alphabet-inc-loss-submission-form?wire=3

Nektar Therapeutics (NASDAQ: NKTR)
Class Period: November 11, 2017 to October 2, 2018
Lead Plaintiff Deadline: December 31, 2018

Throughout the class period, Nektar Therapeutics allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) prior studies which attempted to pegylate IL-2 failed; (2) the extended half-life of the Company's lead I-O candidate, NKTR-214, was unlikely to result in efficacy and created additional high-dosing safety concerns; (3) NKTR-214 was less effective than IL-2 alone; (4) the combination of NKTR-214 with nivolumab has yet to demonstrate significant positive results; and (5) as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times.

Get additional information about the NKTR lawsuit: http://www.kleinstocklaw.com/pslra-1/nektar-therapeutics-loss-submission-form?wire=3

Ryanair Holdings plc (NASDAQ: RYAAY)
Class Period: Purchasers of American Depositary Shares May 30, 2017 - September 28, 2018
Lead Plaintiff Deadline: January 9, 2019

The complaint alleges that throughout the class period Ryanair Holdings plc made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had experienced a breakdown in relations with its employees amidst their growing dissatisfaction with working conditions, lack of benefits, exploitative contracts and management hostility; (b) the Company’s pilots and/or cabin crews had sought union recognition or collectivization in several key markets and employees had internally expressed widespread discontent with the Company’s collective bargaining units; (c) the Company was experiencing elevated and increasing employee turnover, which had resulted in the loss of hundreds of qualified and skilled employees to competitor airlines; (d) the Company’s newly negotiated contracts had not ameliorated employee discontent or “locked away” employee wage growth for three or four years, but rather, defendants were aware that pilot and cabin crew contracts had to be reformulated to significantly increase pay and benefits, comply with local labor laws and provide other worker concessions to enable Ryanair to hire and retain sufficient qualified employees to meet operational targets; (e) because of the aforementioned, the Company was unable to hire sufficient pilots to meet expected demand and was thereby exposed to increased risk of flight cancellations, loss of reputational assets and increased costs from flight disruptions; (f) because of the aforementioned, the Company’s historical operating model and profit growth were not sustainable; and (g) the Company could not meet internal earnings expectations.

Get additional information about the RYAAY lawsuit: http://www.kleinstocklaw.com/pslra-1/ryanair-holdings-plc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com